fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Oxybutynin chloride

All products: not a benefit

Ditropan · DIN 01924761 · 5 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-08-04 — choose a marketed DIN from the same-category list.Discontinued August 4, 2006 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-08-04 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2006-08-04 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Ditropan · DIN 01924761 Manufacturer: Proctor & Gamble Pharmaceuticals Canada, Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2006-08-04 · brand DITROPAN TABLETS 5MG · ATC G04BD04 OXYBUTYNIN · form Tablet · route Oral · ingredients OXYBUTYNIN CHLORIDE 5 MG · company Janssen inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ditropan: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01924761)

Source record
DIN 01924761: Ditropan Raw flags: notABenefit=Y, sec3=Y Item: 120800033; group id 209; item number 0380; lccId None; manufacturer id PGP Source form: Tab; strength: 5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01924761 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14030
Interchangeable products
Apo-Oxybutynin · DIN 02163543 · $0.0986 Novo-Oxybutynin · DIN 02230394 · $0.0986 PMS-Oxybutynin · DIN 02240550 · $0.0986
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01924761
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 4, 2006 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (G04BD): coverage varies; not interchangeable

  • Flavoxate (Urispas): not a benefit
Other drugs in the same formulary class (12:08 Parasympatholytic (Cholinergic Blocking) Agents) and how they are covered

Matched class: 12:08 Parasympatholytic (Cholinergic Blocking) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ACLIDINIUM BROMIDE, BENZTROPINE MESYLATE, ETHOPROPAZINE HCL, GLYCOPYRRONIUM BROMIDE, PROCYCLIDINE HCL, TIOTROPIUM BROMIDE MONOHYDRATE, UMECLIDINIUM Some products covered without a code (check the product listing): IPRATROPIUM BROMIDE, TRIHEXYPHENIDYL HCL 12:08 Parasympatholytic (Cholinergic Blocking) Agents

FLAVOXATE HCL

· 2 products · Listed, not a benefit · strengths: 200mg · Tab

ACLIDINIUM BROMIDE

· 1 products · General benefit · strengths: 400mcg/actuation · Pd Inh-60 Dose Pk

BENZTROPINE MESYLATE

· 1 products · General benefit · strengths: 1mg · Tab

ETHOPROPAZINE HCL

· 1 products · General benefit · strengths: 50mg · Tab

GLYCOPYRRONIUM BROMIDE

· 1 products · General benefit · strengths: 50mcg · Inh Pd-Cap

IPRATROPIUM BROMIDE

· 12 products · Listed, not a benefit (3), Limited Use, codes 256, 257, 258, 259 (3), Limited Use, codes 265, 266, 267, 268 (4), General benefit (2) · strengths: 250mcg/mL, 125mcg/mL, 20mcg/Metered Dose · Inh Sol-20mL Pk, Inh Sol-2mL UDV Pk, Inh-200 Dose Pk

PROCYCLIDINE HCL

· 1 products · General benefit · strengths: 2.5mg · Tab

TRIHEXYPHENIDYL HCL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 2mg, 5mg · Tab

HYOSCINE BUTYLBROMIDE

· 2 products · Limited Use, codes 481 · strengths: 10mg · Tab

IPRATROPIUM BROMIDE/SALBUTAMOL

· 3 products · Listed, not a benefit (1), Limited Use, codes 256, 257, 258, 259 (2) · strengths: 500mcg/2.5mg/2.5mL · Inh Sol-2.5mL Amp Pk

SCOPOLAMINE HYDROBROMIDE

· 4 products · Listed, not a benefit (2), Limited Use, codes 481 (2) · strengths: 0.4mg/mL, 0.6mg/mL · Inj Sol (Preservative Free)

TRIMEBUTINE MALEATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 12:08 and 5 more
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:12 Sympathomimetic (Adrenergic) Agents, 12:20 Skeletal Muscle Relaxants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE APO-OXYBUTYNIN (oxybutynin chloride) is indicated for the relief of symptoms associated with voiding in patients with uninhibited neurogenic bladder and reflex neurogenic bladder (i.e. urgency, frequency, urinary leakage, urge incontinence, dysuria). Geriatrics (> 65 years of age): Clinical studies of oxybutynin chloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between healthy elderly and younger patients. Page 3 of 23 Pediatrics (< 5 years of age): The safety and effectiveness of oxybutynin chloride in pediatric patients under 5 years of age have not been established. https://pdf.hres.ca/dpd_pm/00064481.PDF PM date: January 24, 2022 Source product: APO-OXYBUTYNIN; DIN 02163543; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Ditropan: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026